Symptom prevalence among people affected by advanced and progressive neurological conditions - A systematic review

Journal of Palliative Care

Volumn 23, Issue 4, 2007, Pages 291-297

  Saleem, Tariq ^a   Leigh, P Nigel ^a   Higginson, Irene J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38349095826     PISSN: 08258597     EISSN: None     Source Type: Journal    
DOI: 10.1177/082585970702300408     Document Type: Review

References (61)

1. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease, and renal disease. J Pain Symptom Manage 2006; 31(1): 58-69.
2. rd edition. Oxford: Oxford University Press, 2004.
3. McKenna C, MacLeod R. Access to palliative care for people with motor neurone disease in New Zealand [see comment]. N Z Med J 2005; 16: 118(1222).
4. United Kingdom Department of Health. The National Service Framework for Long-Term Conditions. London: HMSO, 2005.
5. Voltz R, Bernat JL, Borasio GD, Maddocks I, Oliver D, Portenoy RK (eds). Palliative Care in Neurology. Oxford: Oxford University Press, 2004.
6. Addington-Hall J, Higginson I (eds). Palliative Care for Non-Cancer Patients. Oxford: Oxford University Press, 2001.
7. Davies E, Higginson I (eds). Better Palliative Care for Older People. Europe: World Health Organization, 2004.
8. nd edition. Europe: BMJ Blackwell Publishing, 2006.
9. Playford D, Thompson AJ (eds). Neurological Rehabilitation of Parkinson's Disease. London: Taylor and Francis, 2007.
10. Percival R, Hobson P (eds). Parkinson's Disease: studies in psychological and social care. UK: British Psychological Society Blackwell, 1999.
11. Teunissen S, Wesker W, Kruitwagen C, de Haes H, Voest EE dGA. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag 2007; 34(1): 94-104.
12. Lee M, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manag 2006; 32(5): 462-469.
13. Murtagh F.E.M, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14(1): 82-99.
14. Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual Health Care 1999; 8(4): 219-227.
15. Thompson S. Just Invisible. Report on living with the advanced stage of Parkinson's. UK: Parkinson's Disease Society, 2005.
16. National Cancer Research Institute. Report of the NCRI Strategic Planning Group on Supportive and Palliative Care. London: NCRI, 2004.
17. Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The memorial symptom assessment scale short form (MSAS-SF). Cancer 2000; 89(5): 1162-1171.
18. Higginson IJ, Hart S, Silber E, Burman R, Edmonds P. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 2006; 22(3): 158-165.
19. Ganzini L, Johnston WS, Silveira MJ. The final month of life in patients with ALS. Neurology 2002; 59(3): 428-431.
20. O'Brien T, Welsh J, Dunn FG. ABC of palliative care: non-malignant conditions. BMJ 1998; 316: 286-289.
21. O'Brien T, Kelly M, Saunders C. Motor neurone disease: a hospice perspective. BMJ 1992; 304(6825): 471-473.
22. Addington-Hall J, Fakhoury W, McCarthy M. Specialist palliative care in nonmalignant disease. Palliat Med 1998; 12(6): 417-427.
23. Kite S, Jones K, Tookman A. Specialist palliative care and patients with noncancer diagnoses: the experience of a service. Palliat Med 1999; 13(6): 477-484.
24. Norris F. Motor neurone disease: a hospice perspective. BMJ 1992; 304: 459-460.
25. Higginson IJ, Vivat B, Silber E, Saleem T, Burman R, Hart S, et al. Study protocol: delayed intervention randomised controlled trial within the Medical Research Council (MRC) Framework to assess the effectiveness of a new palliative care service. BMC Palliat Care 2006; 5: 7.
26. Hicks F, Corcoran G. Should hospices offer respite admissions to patients with motor neurone disease? Palliat Med 1993; 7(2): 145-150.
27. Charles T, Swash M. Amyotrophic lateral sclerosis: current understanding. [Review.70 refs.] J Neurosci Nurs 2001; 33(5): 245-253.
28. rd edition. Oxford: Oxford University Press; 2004, pp. 925-934.
29. Barby FMT, et al. Palliative care in motor neurone disease. Int J Palliat Nurs 1995; 1(4): 183-184.
30. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med 1992; 83(300): 325-337.
31. Ben-Zacharia AB, Lublin FD. Palliative care in patients with multiple sclerosis. Neurol Clin 2001; 19(4): 801-827.
32. Auspurger RR. Bladder dysfunction in multiple sclerosis. In: Maloney FR Burke JS, Ringel SP (eds). Interdisciplinary Rehabilitation of Multiple Sclerosis and Neuromuscular Disorders. Philadelphia: JB Lippincott; 1985, pp. 48-61.
33. Jones R, D'eath C, Harnsford J, Hutchinson H, Hyde L, Thurlow L, Spanton L. The needs of people with Parkinson's disease and their families: the Parkinson's disease study, Devon and Cornwall, 1989-92. In: Percival R, Hobson P (eds). Parkinson's Disease: studies in psychological and social care; 1999, p. 60-78.
34. Sjostrom A, Holmberg B, Strang P. Parkinson-plus patients - an unknown group with severe symptoms. J Neurosci Nurs 2002; 34(6): 314-319.
35. Newrick PG, Langton-Hewer R. Motor neurone disease: Can we do better? A study of 42 patients. BMJ Clin Res Ed 1984; 289(6444): 539-542.
36. Brooks DJ. Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2002; 72(suppl 1): 110-116.
37. Kiebert GM, Green C, Murphy C, Mitchell JD, O'Brien M, Burrell A, et al. Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci 2001; 191(1-2): 87-93.
38. Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003; 18(10): 1139-1145.
39. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-doparesponsive problems dominate at 15 years. Mov Disord 2005; 20(2): 190-199.
40. Oxtoby M. Parkinson's Disease Patients and Their Social Needs. Parkinson's Disease Society, 1982.
41. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson's disease? J Neurol 2002; 249(4): 419-423.
42. Clough C, Blockley A. Parkinson's disease and related disorders. In: Voltz R, Bernat JL, Borasio GD, Maddocks I, Oliver D, Portenoy RK (eds). Palliative Care in Neurology. Oxford: Oxford University Press; 2006, pp. 48-58.
43. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52(7): 1311-1323.
44. Oliver D. The quality of care and symptom control - the effects on the terminal phase of ALS/MND. J Neurol Sci 1996; 139(suppl): 134-136.
45. Mandler RN, Anderson FA, Jr., Miller RG, Clawson L, Cudkowicz M, Del BM, et al. The ALS Patient Care Database: insights into end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2(4): 203-208.
46. Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248(7): 612-616.
47. Ehde DM, Gibbons LE, Chwastiak L, Bombardier CH, Sullivan MD, Kraft GH. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler 2003; 9(6): 605-611.
48. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord 1986; 1(1): 45-49.
49. Tison F, Wenning GK, Volonte MA, Poewe WR, Henry P, Quinn NP. Pain in multiple system atrophy. J Neurol 1996; 243(2): 153-156.
50. Nilsson H, Ekberg O, Olsson R, Hindfelt B. Quantitative aspects of swallowing in an elderly nondysphagic population [see comment]. Dysphagia 1996; 11(3): 180-184.
51. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992; 46(12): 879-884.
52. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003; 2(2): 107-116.
53. Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 2004; 30(2): 95-105.
54. Boyce HW, Bakheet MR. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol 2005; 39(2): 89-97.
55. Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66(4): 431-435.
56. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13(1): 42-49.
57. Hunter MD, Robinson IC, Neilson S. The functional and psychological status of patients with amyotrophic lateral sclerosis: some implications for rehabilitation. Disabil Rehabil 1993; 15(3): 119-126.
58. Hogg KE, Goldstein LH, Leigh PN. The psychological impact of motor neurone disease. Psychol Med 1994; 24(3): 625-632.
59. Grossman A, Bradley W. Psychosocial factors and cognition in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4(4): 217-224.
60. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20(8): 958-963.
61. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123(Pt 4): 733-745.